Coxsackievirus A10 (CV-A10) has lately emerged as a significant pathogen of hand, foot, and mouth disease (HFMD) in children all over the world. There are currently no viable therapies; the development of an anti-CV-A10 vaccination is the most cost-effective method of CV-A10 prophylaxis. A robust test for measuring neutralising antibody titres produced by vaccination would substantially accelerate the development of an anti-CV-A10 vaccine. In contrast to the standard neutralisation assay based on cytopathic effect inhibition, which is time-consuming and labor-intensive, we devised an efficient high-throughput neutralisation antibody assay based on CV-A10 pseudoviruses in this work (referred to as pNT).

In the pNT, anti-CV-A10 NtAb titre correlated adversely with the relative luminous unit (RLU) generated by the luciferase reporter gene included in the pseudovirus genome. According to this study, NtAb against CV-A10 could be detected within 10–16 h, anti-CV-A10 NtAb in 67 human serum samples were measured in parallel with pNT and cNT assays, a good correlation and good agreement (97 percent ) were shown between cNT and pNT, indicating that the pNT provides a rapid and convenient procedure for measuring NtAb production against anti-CV-A.